MX2012001461A - Preparacion farmaceutica, de administracion oral, que contiene insulina. - Google Patents

Preparacion farmaceutica, de administracion oral, que contiene insulina.

Info

Publication number
MX2012001461A
MX2012001461A MX2012001461A MX2012001461A MX2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A MX 2012001461 A MX2012001461 A MX 2012001461A
Authority
MX
Mexico
Prior art keywords
pharmaceutical preparation
preparation containing
orally administerable
containing insulin
administerable pharmaceutical
Prior art date
Application number
MX2012001461A
Other languages
English (en)
Spanish (es)
Inventor
Szilvassy Dr Zoltan
Peitl Dr Barna
Nemeth Dr Jozsef
Original Assignee
Cera Med Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cera Med Kft filed Critical Cera Med Kft
Publication of MX2012001461A publication Critical patent/MX2012001461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2012001461A 2009-08-03 2010-08-02 Preparacion farmaceutica, de administracion oral, que contiene insulina. MX2012001461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0900482A HUP0900482A2 (en) 2009-08-03 2009-08-03 Pharmaceutical formulation for oral administration
PCT/IB2010/053499 WO2011015984A1 (en) 2009-08-03 2010-08-02 Orally administerable pharmaceutical preparation containing insulin

Publications (1)

Publication Number Publication Date
MX2012001461A true MX2012001461A (es) 2012-05-22

Family

ID=89989155

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001461A MX2012001461A (es) 2009-08-03 2010-08-02 Preparacion farmaceutica, de administracion oral, que contiene insulina.

Country Status (15)

Country Link
US (1) US20120129769A1 (enExample)
EP (1) EP2461820A1 (enExample)
JP (1) JP2013501043A (enExample)
KR (1) KR20120088660A (enExample)
CN (1) CN102791282A (enExample)
AU (1) AU2010280418B2 (enExample)
BR (1) BR112012002413A2 (enExample)
CA (1) CA2769620A1 (enExample)
HU (1) HUP0900482A2 (enExample)
IL (1) IL217856A0 (enExample)
MX (1) MX2012001461A (enExample)
RU (1) RU2012109006A (enExample)
UA (1) UA106506C2 (enExample)
WO (1) WO2011015984A1 (enExample)
ZA (1) ZA201201519B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2773115T3 (es) * 2011-06-29 2020-07-09 Rani Therapeutics Llc Preparados de agentes terapéuticos para la administración hacia el interior de una luz del tubo intestinal utilizando un dispositivo tragable para la administración de fármacos
EP3645736B1 (en) 2017-06-28 2022-06-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Method for determining the risk to develop type 1 diabetes
KR102996732B1 (ko) 2023-05-30 2026-07-29 (주)네오비젼 당뇨병 치료를 위한 약물 방출 제어가 가능한 약물 전달용 콘택트렌즈

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172814A (en) 1962-04-06 1965-03-09 Jr Edgar A Ferguson Oral blood sugar lowering compositions
JPS5428807A (en) 1977-08-09 1979-03-03 Hiroyuki Sumi Oral insulin
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
EP0351651B1 (en) 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulin preparation
DK0615444T3 (da) 1991-12-05 1996-07-08 Alfatec Pharma Gmbh Peroral indgivelsesform til peptidlægemidler, især insulin
JP3047948B2 (ja) * 1992-12-07 2000-06-05 株式会社ツムラ ペプチド類経鼻投与用組成物
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1995033474A1 (en) * 1994-06-03 1995-12-14 Tsumura & Co. Medicinal composition
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5970193A (en) 1996-10-24 1999-10-19 Nortel Networks Corporation Data communications structures relating to data shelf configurations
EP0975328A1 (en) 1997-04-02 2000-02-02 Purdue Research Foundation Method for oral delivery of proteins
JP2002531518A (ja) 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
WO2004078198A1 (en) 2003-03-04 2004-09-16 The Technology Development Company Ltd. Long acting injectable insulin composition and methods of making and using thereof
JP5103748B2 (ja) * 2005-02-16 2012-12-19 東レ株式会社 医薬組成物
EP2722054B1 (en) * 2005-09-06 2018-03-21 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
CN101062408B (zh) * 2006-04-27 2010-12-08 深圳市隆阳生物科技有限公司 口服胰岛素复合制剂及其制备方法
JP2008266179A (ja) * 2007-04-19 2008-11-06 Fujifilm Corp 経肺用組成物
EP2514406A1 (en) * 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
CN102123697B (zh) * 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物

Also Published As

Publication number Publication date
US20120129769A1 (en) 2012-05-24
AU2010280418A1 (en) 2012-03-22
KR20120088660A (ko) 2012-08-08
HUP0900482A2 (en) 2011-03-28
ZA201201519B (en) 2013-05-29
AU2010280418B2 (en) 2015-04-09
HU0900482D0 (en) 2009-10-28
WO2011015984A1 (en) 2011-02-10
UA106506C2 (uk) 2014-09-10
CA2769620A1 (en) 2011-02-10
IL217856A0 (en) 2012-03-29
BR112012002413A2 (pt) 2016-03-01
EP2461820A1 (en) 2012-06-13
JP2013501043A (ja) 2013-01-10
CN102791282A (zh) 2012-11-21
RU2012109006A (ru) 2013-09-10

Similar Documents

Publication Publication Date Title
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
MX336412B (es) Nuevos analogos de glucagon.
MY167234A (en) Novel glucagon analogues
UA109949C2 (uk) Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання
UA103526C2 (ru) Воспроизведенный сурфактант, который содержит аналоги белков естественных сурфактантов sp-b и sp-c
IN2014KN02830A (enExample)
MX2013011175A (es) Analogos de glucagon novedosos.
NZ599774A (en) Melanocortin-1 receptor-specific cyclic peptides
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
PH12016500004A1 (en) Pcsk9 vaccine
PH12014500923A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
UA113729C2 (xx) Мутантний поліпептид інтерлейкіну-2 (il-2)
IN2012DN00639A (enExample)
EA201070046A1 (ru) Способ получения лекарственного средства, содержащего тадалафил
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
PH12013501902A1 (en) Infant formula for use in the prevention of cardiovascular diseases
WO2009002159A3 (en) Intradermal hpv peptide vaccination
WO2012142413A3 (en) Nitrite compositions and uses thereof
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
UA106506C2 (uk) Інсулінвмісний фармацевтичний препарат для перорального застосування
WO2012062873A3 (en) Highly immunogenic hiv p24 sequences
WO2023285686A3 (en) Recombinant variants of r-spondin proteins and their use
WO2011081424A3 (ko) 통풍 개선 효과가 있는 기능성식품과, 김치, 고추장, 된장, 간장 등의 기능성 발효식품 및 그 제조방법

Legal Events

Date Code Title Description
FA Abandonment or withdrawal